Summary & Overview
HCPCS C9053: Crizanlizumab-tmca Injection, 1 mg
HCPCS Level II code C9053 designates the injectable biologic agent crizanlizumab-tmca billed per milligram (1 mg unit). Crizanlizumab-tmca is used as an intravenous monoclonal antibody therapy in conditions where this agent is clinically indicated; reporting by milligram allows precise capture of administered dose for billing and utilization monitoring. Nationally, accurate coding of high-cost biologics like crizanlizumab-tmca matters for payment integrity, utilization review, and care coordination across inpatient and outpatient infusion settings.
Key payers addressed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare and Medicare. Readers will find a concise overview of the code’s clinical context, typical sites where the service is delivered (infusion centers, hospital outpatient departments, and physician offices), and what to expect in payer coverage discussions. The publication outlines benchmarks for billing unitization, identifies common areas of policy focus such as dose-based reporting and site-of-service distinctions, and summarizes implications for revenue cycle workflows and claims adjudication. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code C9053 represents the drug product injection, crizanlizumab-tmca, 1 mg. This code is used to report administration of the monoclonal antibody therapy crizanlizumab-tmca by dosage in milligrams.
-
Service Type: Injectable biologic therapy
-
Typical Site of Service: Infusion or outpatient infusion center; may also be administered in hospital outpatient departments or physician offices depending on clinical setting and payer policies
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with sickle cell disease experiencing frequent vaso-occlusive crises despite standard disease-modifying therapy. The patient presents to an outpatient infusion center for administration of C9053 (crizanlizumab-tmca), a monoclonal antibody given intravenously to reduce the frequency of pain crises. Clinical workflow: pre-visit nurse assessment (vitals, review of recent crises, medication reconciliation), verification of diagnosis and prior authorization, pharmacy prepares C9053 per weight-based dosing, IV access placement, medication administration with monitoring for infusion reactions, documentation of lot number and dose, observation for 30–60 minutes post-infusion, and billing using C9053 with appropriate visit and infusion-related CPT codes recorded separately.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
25 | Significant, separately identifiable evaluation and management service by the same physician on the same day of the procedure or other service | Use when an E/M visit is provided on the same day as the infusion and meets E/M documentation requirements |